Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
Related Articles
Why MAHA wants whole milk back on the table
In the nutrition world, the question of how whole milk compares with lower-fat options is the subject of debate. In MAHA world, it’s time to…
As AI device market grows, FDA’s accounting goes silent
As the market for AI enabled medical devices grows, experts say there is less transparency around device approvals.
Six former CDC vaccine advisory committee chairs warn: U.S. risks losing access to life-saving immunizations
“We are witnessing a dismantling of the systems that develop, license, recommend, and monitor vaccines,” write six former chairs of the CDC’s vaccine advisory committee.
The MAHA children’s health report mis-cited our research. That’s sloppy — and worrying
Being cited in a major government report, like the MAHA report on children’s health, should be gratifying. Not this time.
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.
Top gene therapy regulator forced out at FDA
Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy Rachael Anatol have been
U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.
Brain implant captures speech tone, pitch through analyzing activity
New brain-computer interface reduced time lag in translating thoughts into speech in a meaningful advance for the field.
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
FDA’s gene therapy turmoil, and an alternative model for funding research
Why did the Food and Drug Administration suddenly oust one of its top gene therapy regulators?